Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Will Arena Compete With Its Partner?

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

Investors today commonly associate the obesity market with three main players: Orexigen  (Nasdaq: OREX  ) , which is still developing its drugs Contrave and Empatic, VIVUS (Nasdaq: VVUS  ) , which recently launched its therapeutic Qsymia, and Arena Pharmaceuticals  (Nasdaq: ARNA  ) , which gained FDA approval for Belviq back in June and is poised to launch the drug with its partner Eisai.

Interestingly, a recent study showed that one of Eisai's epilepsy drugs, called Zonegran, may also be a potential weight-loss medicine. In the following video, health-care analysts Max Macaluso and David Williamson analyze this story and identify some things Arena investors should watch in both the near and long term.

Arena's stock has gone up by more than 400% year to date, but investors need to keep up with industry dynamics to determine where the stock will go from here. While the future looks bright for this company, there are still plenty of obstacles ahead. In our premium research report on Arena Pharmaceuticals, senior biotech analyst Brian Orelli, Ph.D., walks investors through the opportunities and threats facing the company. Click here now to learn more.

Max Macaluso, Ph.D., David Williamson, and The Motley Fool have no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2062778, ~/Articles/ArticleHandler.aspx, 10/21/2016 6:21:38 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,145.71 -16.64 -0.09%
S&P 500 2,141.16 -0.18 -0.01%
NASD 5,257.40 15.57 0.30%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/21/2016 4:00 PM
ARNA $1.57 Down -0.02 -1.26%
Arena Pharmaceutic… CAPS Rating: **
OREX $2.82 Up +0.04 +1.44%
Orexigen Therapeut… CAPS Rating: *
VVUS $1.10 Down -0.01 -0.90%
VIVUS CAPS Rating: **